Antibody inducing Immunotherapies

**Shape is developing programmable multi-target antibody-inducing immunotherapies for cardiometabolic disease, I&I and immunooncology targets based on its proprietary SHAPEnano platform (see below).

Seeking partners with innovative in vivo and in vitro models, delivery technologies (e.g. patch, spray) for potential collaborative project (e.g. Pathfinder, Eurostars), complementary modalities, potential for combination regimens and epitope discovery platforms (e.g. neoantigen epitopes for cancer vaccine design).

Our SHAPEnano platfrom at a glance:

Design:
- Fully synthetic, sequence-define lipopeptides
- Engineered multi-epitope presentation
- Self-assembling nanoparticles with controlled composition

Immune Engagement:
-Robust sustained responses (IgG antibody titers > 10^4-10^6) without external adjuvants

Manufacturing & Scale:
- Single component, molecularly defined entity
- Scalable via standard peptide manufacturing

**